Lung cancer

  • Preparation of 3 existing manuscripts on lung cancer for submission
  • Literature search and analysis of phase 2 vs phase 3 lung cancer studies
  • Literature and reimbursement review of intravenous versus subcutaneous therapies in lung cancer
  • Development of a pan-lung oncology treatment model
  • Landscape analysis for ablation in lung cancer
  • Patient interviews in lung cancer
  • Analyses of endpoints in oncology: Statistical analyses in lung cancer
  • Analyses of endpoints in oncology: Country-specific EQ-5D utilities in lung cancer
  • Analytical evidence for improvement in symptoms and quality of life in lung cancer patients on a specified treatment
  • Analytical evidence for improvement in symptoms and quality of life in pre and post-randomisation lung cancer patients (by age groups)
  • Strategic consulting, research and measurement in solid tumours
  • Strategic communications planning in lung cancer
  • Consulting for an FDA submission in lung cancer
  • Summary presentation of a workstream in lung cancer

Non-small cell lung cancer (NSCLC)

  • Global value dossier and e-v@luate platform in NSCLC
  • Global value dossier and e-v@luate platform in non-squamous NSCLC
  • Global value dossier and e-v@luate platform in advanced squamous NSCLC
  • Global value dossier for a treatment in metastatic NSCLC
  • Payer value deck and response to payer questions update in 1st line NSCLC
  • Updated payer value dossier deck and FAQs deck for 1st line NSCLC
  • Updated burden of disease decks, payer value dossier decks and FAQs decks for 1st line and 2nd line NSCLC
  • Societal costs, health-related quality of life systematic literature review and publications plan for NSCLC in Europe
  • Literature review of overall survival and bone metastases in NSCLC
  • Literature review to inform global market access materials in NSCLC
  • Structured literature review in advanced 1st line NSCLC
  • Systematic review and mixed treatment comparison in advanced NSCLC
  • Development of technical documentation and manuscript on NSCLC
  • Two manuscripts on the indirect comparison of the efficacy of two different therapies for NSCLC
  • Development of a manuscript on the cost-effectiveness of a treatment in NSCLC in Italy
  • Manuscript on the efficacy of three different drugs for the treatment of NSCLC
  • Model review of a drug used in the treatment of NSCLC
  • Multi-indication budget impact model in NSCLC
  • Adaptation of a multi-indication value-based pricing model in NSCLC to China
  • Value-based model in NSCLC
  • Standardisation of economic models in NSCLC
  • Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on NSCLC
  • Burden of disease decks in advanced 1st line and 2nd line NSCLC
  • Burden of disease deck update in 1st line NSCLC
  • Integrated research plan in advanced melanoma and NSCLC
  • Value slide deck for treatment in NSCLC
  • Guidance documents for affiliates in treatment for NSCLC
  • Situational analysis report of epidermal growth factor receptor (EGFR) predictive testing in NSCLC
  • Communication toolkit for a lung cancer supplement
  • Companion diagnostics biomarker FAQs compilation deck in NSCLC
  • FAQs update in advanced 1st line NSCLC
  • FAQs deck update in 2nd line NSCLC
  • Payer slide decks and objection handler in NSCLC
  • Payer tools implementation guide in NSCLC
  • Payer value proposition deck update in 2nd line NSCLC
  • Payer value deck update in advanced 1st line NSCLC
  • Payer value deck and response to payer questions update in 1st line NSCLC
  • HTA submission support in epidermal growth factor receptor positive (EGFR+) and non-small cell lung cancer (NSCLC)
  • Numerous abstracts and conference posters on NSCLC, advanced NSCLC and related treatments
  • Several abstracts and conference posters relating to the cost and cost effectiveness of a first-line treatment option for patients with NSCLC
  • Abstract and poster on progression-free survival and overall survival in patients with NSCLC
  • Literature review of outcomes and costs during treatment for advanced NSCLC
  • Literature review and consultancy on NSCLC
  • Manuscript on stage IIIb and IV NSCLC
  • Development of a measurement dossier in advanced NSCLC for the EMA
  • Meta-analysis and manuscript on stage IIIb and IV NSCLC
  • Statistical analyses of clinical trial data (safety study) in NSCLC
  • Statistical analyses of clinical trial data (observational study) in NSCLC
  • Clinical trial analyses to support health-related quality of life in first-line NSCLC
  • Qualitative study on the needs and preferences of patients with advanced NSCLC for maintenance therapy
  • Development of an analysis plan in NSCLC for the USA and Europe
  • Analysis of PRO data in NSCLC
  • Qualitative interviews to understand the impact of NSCLC on quality of life and on caregivers and family members
  • EQ-5D review for an EMA measurement dossier in advanced NSCLC
  • Exploratory qualitative interviews in NSCLC patients to assess progression-free survival
  • Comparative effectiveness of two treatments for the treatment of NSCLC
  • Feasibility network meta-analysis comparison of two treatments for NSCLC
  • Exploratory analysis of the Visual Symptom Assessment Questionnaire (VSAQ) in patients who have undergone treatment for NSCLC
  • Utilities analyses to support economic modelling in NSCLC
  • Clinical trial analyses to support health-related quality of life in NSCLC
  • Impact of whole brain radiation therapy in patients with NSCLC with brain metastases

Small cell lung cancer (SCLC)

  • Global value dossier and upload to e-v@luate platform in SCLC
  • AMCP dossier in SCLC
  • Systematic literature reviews for the societal and health-related quality of life burden of SCLC
  • Systematic literature review and manuscript on real-world effectiveness and tolerability of treatments in SCLC
  • Literature review on real-world effectiveness and tolerability of treatment in SCLC
  • Utility study in SCLC
  • Development of a budget impact model in SCLC
  • Budget impact model in 1st line SCLC
  • Development of a disease conceptual model and endpoint recommendation for SCLC
  • Phase IV clinical trial analysis of two drugs used in the treatment of SCLC
  • Analysis of symptoms for a drug used to treat SCLC
  • Full text reports on the longitudinal analyses of a drug used to treat SCLC for EU submission
  • Literature and PRO strategy for SCLC
  • Clinical trial analyses to support health-related quality of life in SCLC
  • Literature review and consultancy on SCLC

Related categories

Experience,  Oncology,  Therapeutic area